Industry funding collapsed 93% from $989M (2021) to $65M (2025)

Investment in cultivated meat startups plummeted from a peak of $989 million in 2021 to just $65 million in 2025 — a 93% decline in four years. In the first nine months of 2025, the sector raised only $36 million total. So what? Companies that raised money at 2021 valuations on 3-5 year runway projections are now running out of cash with no ability to raise follow-on funding. Believer Meats shut down in late 2025 despite having built a 200,000 sq ft production facility in North Carolina capable of 12,000 tonnes/year. Dutch startup Meatable dissolved in December 2025. UPSIDE Foods went through multiple rounds of layoffs and paused construction of its planned large-scale facility. So what? The scientists, bioprocess engineers, and food scientists who spent years developing expertise in this niche are being laid off and dispersing into other industries, destroying accumulated institutional knowledge. So what? When (if) the technology matures and funding returns, the industry will need to rebuild human capital from scratch, adding years to the commercialization timeline. So what? This creates a self-reinforcing doom loop: lack of progress discourages investors, lack of investment prevents progress, lack of progress further discourages investors. Why does this persist? The core problem is that cultivated meat requires pharma-level capital intensity ($100M+ for a single production facility) but targets food-level margins (5-15% gross margins vs 60-80% in pharma). Venture capital expected tech-startup-style returns, but the business model structurally cannot deliver them at current technology readiness levels.